EFFICACY
Review efficacy data against RSV-LRTD for your patients aged 60 years and older.1
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
By combining the RSVPreF3 antigen with an adjuvant system (AS01E), AREXVY induces antigen-specific cellular immune response and neutralising antibodies that help protect against RSV-associated LRTD.1
Abbreviations
LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; RSVPreF3=recombinant RSV glycoprotein F stabilised in the pre-fusion conformation.
References
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
©2024 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
PM-IE-RSA-WCNT-230002 | May 2024